rules for prescribing Strattera

If you’ve been wondering whether you can access ADHD treatment from home, you’re not alone. Millions of Americans are discovering that telehealth offers a convenient, effective path to managing attention-deficit/hyperactivity disorder—especially when it comes to non-stimulant medications like Strattera (atomoxetine).

The short answer? Yes, you absolutely can get ADHD non-stimulant medication through telehealth. In fact, non-stimulant ADHD medications face fewer regulatory hurdles than their stimulant counterparts, making them particularly accessible through virtual care platforms.

But there’s more to the story. Understanding the nuances of telehealth ADHD treatment—from federal regulations to state-specific rules—can help you navigate your options with confidence and find the care that works best for your lifestyle.

Understanding ADHD Non-Stimulant Medications

What Are Non-Stimulant ADHD Medications?

Non-stimulant medications offer an alternative approach to managing ADHD symptoms. Unlike stimulants such as Adderall or Ritalin, these medications work differently in the brain and carry distinct advantages for certain patients.

Strattera (atomoxetine) is the most commonly prescribed non-stimulant ADHD medication. It works by increasing norepinephrine levels in the brain, which helps improve attention, focus, and impulse control. Crucially, Strattera is not classified as a controlled substance by the DEA, which has significant implications for telehealth prescribing.

Other non-stimulant options include:

• Guanfacine (Intuniv) – Originally a blood pressure medication, now FDA-approved for ADHD
• Clonidine (Kapvay) – Also helps with hyperactivity and impulsivity
• Viloxazine (Qelbree) – A newer non-stimulant option approved in 2021

Why Choose a Non-Stimulant?

Non-stimulant medications may be the right choice if you:

• Have a history of substance abuse or concern about dependency
• Experience uncomfortable side effects from stimulants (like sleep problems or appetite loss)
• Have certain heart conditions that make stimulants risky
• Prefer a medication that provides steady, all-day symptom control
• Need coverage throughout the evening hours (stimulants often wear off)
• Want to avoid the monthly prescription refill requirements of controlled substances

While non-stimulants typically take 4-6 weeks to reach full effectiveness (compared to same-day results with stimulants), many patients find the trade-off worthwhile for the benefits of consistent symptom management without the ups and downs.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

The Legal Landscape: Federal Telehealth Rules for ADHD Medications

DEA Regulations: What You Need to Know

The regulatory environment for telehealth ADHD treatment has been evolving rapidly since 2020. Understanding these rules helps clarify why non-stimulant medications are particularly accessible through virtual care.

For non-stimulant medications like Strattera: There are no federal restrictions on telehealth prescribing. Because these medications aren’t controlled substances, they aren’t subject to the Ryan Haight Act’s in-person examination requirement. A licensed provider can evaluate you via video, confirm your ADHD diagnosis, and electronically prescribe Strattera if clinically appropriate—all without requiring an in-person visit.

For stimulant medications (Schedule II controlled substances): The situation is more complex. The DEA’s pandemic-era telehealth flexibilities currently allow providers to prescribe controlled substances via telehealth without a prior in-person exam. However, this temporary rule is set to expire on December 31, 2025. A fourth extension for 2026 is anticipated and currently under review, but the future remains somewhat uncertain.

The Ryan Haight Act: Why It Matters

Passed in 2008, the Ryan Haight Online Pharmacy Consumer Protection Act was designed to prevent illegal online pharmacies from dispensing controlled substances. The law generally requires an in-person medical evaluation before a provider can prescribe controlled medications.

During the COVID-19 public health emergency, the DEA waived this requirement for telehealth providers treating established or new patients. This waiver has been extended multiple times and currently runs through the end of 2025.

The key takeaway: If you’re seeking non-stimulant ADHD medication, the Ryan Haight Act doesn’t apply to you. Your telehealth provider can prescribe these medications following the same standards they would use in an office visit—no special federal restrictions apply.

State-by-State Telehealth Rules: What You Should Know

While federal law sets the baseline, individual states have their own telehealth regulations that can impact your access to ADHD treatment. Let’s break down what you need to know for major states:

California: Telehealth-Friendly with Evolving Standards

California allows telehealth for ADHD treatment without mandating in-person visits for non-controlled medications. Nurse practitioners in California have gained independent practice authority (under AB 890), meaning qualified NPs can diagnose and treat ADHD without physician oversight.

Recent legislative activity (AB 1503) has proposed clarifying that a telehealth examination satisfies the requirement for establishing a patient-provider relationship before prescribing. While still pending, this reflects California’s commitment to expanding telehealth access.

New York: Stricter Rules for Controlled Substances

New York adopted a final rule in May 2025 that reinstated in-person examination requirements for prescribing controlled substances via telehealth. This means if you’re seeking stimulant medications in New York, you’ll need an initial in-person evaluation.

However, this restriction doesn’t apply to non-controlled medications like Strattera. New York residents can access non-stimulant ADHD treatment entirely through telehealth. Nurse practitioners in New York also enjoy independent practice authority after completing 3,600 hours of experience.

Florida: Psychiatric Exceptions Create Access

Florida has specific rules about Schedule II prescribing via telehealth, generally prohibiting it unless the medication is prescribed for a psychiatric disorder (which ADHD is), or the patient is hospitalized, in hospice, or in a nursing facility. Fortunately, this psychiatric exception means ADHD treatment—both stimulants and non-stimulants—remains accessible via telehealth.

Florida requires providers to check the state’s Prescription Drug Monitoring Program (PDMP) before every controlled substance prescription, though this doesn’t apply to non-controlled medications like Strattera.

Texas: Mental Health Telehealth Embrace

Texas has been particularly supportive of telehealth for mental health care. The state allows telemedicine for behavioral health and chronic conditions without requiring in-person visits for ADHD treatment.

One important note: Texas restricts nurse practitioners and physician assistants from prescribing Schedule II stimulants except in hospital or hospice settings. However, physicians can prescribe all ADHD medications via telehealth, and NPs/PAs can prescribe non-stimulant options with their collaborative practice agreements.

New Hampshire: Recent Expansion of Access

New Hampshire made significant changes in August 2025 with SB 252, which removed previous in-person requirements for telehealth prescribing of controlled substances. The state now only requires an annual follow-up evaluation (which can be conducted via telehealth) for ongoing controlled medication prescriptions.

This makes New Hampshire one of the more progressive states for telehealth ADHD treatment, with nurse practitioners enjoying full independent practice and prescribing authority.

Alabama: Stricter Protocols Remain

Alabama maintains some of the strictest telehealth prescribing rules in the country. The state generally requires an in-person visit within 12 months for ongoing telehealth treatment of the same condition. However, mental health services are exempt from this requirement, which may apply to psychiatric ADHD care.

For controlled substances, Alabama has additional requirements that can make stimulant prescribing more challenging via telehealth, though non-stimulant medications face fewer barriers.

The Telehealth ADHD Evaluation Process

What to Expect During Your Virtual Visit

A legitimate telehealth ADHD evaluation should be just as thorough as an in-person assessment. Here’s what a comprehensive evaluation typically includes:

1. Initial Intake and Screening

• Detailed questionnaires about your symptoms
• Assessment of how symptoms impact work, school, and relationships
• Questions about symptom onset (ADHD symptoms must begin in childhood)
• Review of your medical history and current medications
• Mental health screening for conditions like anxiety or depression

2. Diagnostic Interview

• Video consultation with a licensed provider (MD, DO, or qualified NP)
• Discussion of DSM-5 criteria for ADHD (inattention, hyperactivity, impulsivity)
• Questions about symptoms in multiple settings
• Review of any previous diagnoses or treatments
• Sometimes collateral information from family members or partners

3. Treatment Planning

• Discussion of medication and non-medication options
• Explanation of different ADHD medications and their effects
• Consideration of your specific symptoms, lifestyle, and preferences
• Review of potential side effects and contraindications
• Development of a monitoring and follow-up plan

4. Prescription and Follow-Up

• Electronic prescription sent to your preferred pharmacy
• Scheduling of follow-up appointments (typically within 2-4 weeks)
• Instructions for monitoring symptoms and side effects
• Contact information for questions or concerns

Documentation You May Need to Provide

To ensure an accurate diagnosis and safe treatment, be prepared to provide:

• Identity verification (government-issued ID)
• Insurance information (if applicable)
• Previous medical records (especially any prior ADHD assessments)
• Current medication list
• School records (report cards showing childhood attention issues can be helpful for adult diagnoses)
• Work performance reviews (if relevant to demonstrating functional impairment)

Red Flags: What Legitimate Providers Won’t Do

Beware of telehealth services that:

• Guarantee a prescription before evaluation
• Skip comprehensive symptom assessment
• Don’t require video consultation (phone-only isn’t adequate)
• Offer to prescribe after just a brief questionnaire
• Don’t verify your identity or medical history
• Promise immediate prescriptions for controlled substances without proper evaluation

The investigations into companies like Cerebral and Done in 2022-2023 highlighted the dangers of inadequate ADHD evaluations. Legitimate providers prioritize patient safety over convenience.

Strattera and Other Non-Stimulants: Telehealth Prescribing Details

Why Strattera Is Particularly Well-Suited for Telehealth

Strattera’s classification as a non-controlled substance offers several advantages for telehealth patients:

Flexible Prescribing

• Can be prescribed for 90-day supplies (unlike 30-day limits for stimulants)
• Allows for refills without monthly provider check-ins
• No special DEA requirements or prescription limitations
• Can be called in or e-prescribed without special EPCS (Electronic Prescribing for Controlled Substances) systems

Reduced Regulatory Barriers

• Not subject to Prescription Drug Monitoring Program (PDMP) mandatory checks in most states
• No federal in-person examination requirements
• Fewer state-level restrictions compared to Schedule II medications
• Less pharmacy scrutiny when filling prescriptions

Clinical Considerations

• Lower abuse potential makes it appropriate for patients with substance use history
• Steady therapeutic effect throughout the day (no ‘wearing off’)
• Once-daily dosing option improves compliance
• Cardiovascular safety profile suitable for many patients who can’t take stimulants

Starting Strattera Via Telehealth: What to Expect

Initial Dosing and TitrationYour provider will likely start you on a low dose (typically 40mg daily for adults) and gradually increase based on your response. This titration process can be effectively managed through telehealth:

• Week 1-2: Starting dose, monitoring for side effects
• Week 3-4: First follow-up, possible dose adjustment
• Week 6-8: Assessment of therapeutic effect, further titration if needed
• Month 2-3: Stabilization on optimal dose

Monitoring and Follow-UpRegular virtual check-ins will assess:

• Symptom improvement (attention, focus, organization)
• Side effects (nausea, decreased appetite, mood changes)
• Blood pressure and heart rate (you may need a home monitor)
• Any signs of suicidal thinking (FDA black box warning requires monitoring, especially in young adults)
• Overall functioning in work, school, and relationships

Timeline to EffectivenessSet realistic expectations: Strattera typically takes 4-6 weeks to reach full therapeutic benefit. This is different from stimulants, which work the first day. Your provider should discuss this timeline and help you track gradual improvements.

Who Can Prescribe ADHD Medications Via Telehealth?

Physicians (MD and DO)

In all 50 states, licensed physicians can prescribe both stimulant and non-stimulant ADHD medications via telehealth, provided they:

• Hold an active license in the patient’s state
• Have appropriate DEA registration (for controlled substances)
• Follow state-specific telehealth and prescribing regulations
• Maintain proper documentation and standard of care

Psychiatrists and primary care physicians commonly treat ADHD, though any licensed physician with appropriate training can provide this care.

Nurse Practitioners (NPs)

Nurse practitioner prescribing authority varies significantly by state:

Full Practice Authority States (Independent NP Prescribing)States like California, New York, Illinois, and New Hampshire allow experienced NPs to diagnose and treat ADHD independently, including prescribing both stimulant and non-stimulant medications (after meeting experience requirements).

Collaborative Practice StatesStates like Florida and Pennsylvania require NPs to have physician collaborative agreements. In these states, NPs can still prescribe ADHD medications, but within the framework of their collaboration agreement.

Restricted Practice StatesSome states, like Georgia and Texas, have specific limitations on what NPs can prescribe:

• Georgia: NPs cannot prescribe Schedule II stimulants even under supervision
• Texas: NPs can only prescribe Schedule II medications in hospital or hospice settings

For non-stimulant medications: Nearly all states allow NPs to prescribe Strattera and other non-controlled ADHD medications under collaborative practice agreements or independent authority.

Physician Assistants (PAs)

PAs typically practice under physician supervision or delegation agreements. Their prescribing authority for ADHD medications depends on:

• State PA practice laws
• Scope defined in their delegation agreement
• Practice setting (hospital vs. outpatient)
• DEA registration and state requirements

Most states allow PAs to prescribe non-stimulant ADHD medications with appropriate physician oversight.

Insurance, Cost, and Access Considerations

Insurance Coverage for Telehealth ADHD Treatment

Most insurance plans now cover telehealth visits at parity with in-person care, thanks to pandemic-era policy changes that many states have made permanent. However, coverage specifics vary:

What’s Typically Covered:

• Initial diagnostic evaluations
• Follow-up medication management visits
• Prescription medications (formulary-dependent)
• Some plans cover therapy or ADHD coaching

What to Verify:

• Whether your provider is in-network
• If prior authorization is required for ADHD medications
• Copay amounts for telehealth vs. in-person visits
• Whether your plan covers out-of-state telehealth providers

Cash-Pay Options and Transparent Pricing

For patients without insurance or those preferring not to use it, many telehealth platforms offer transparent cash-pay pricing. Klarity Health, for example, provides clear upfront pricing and accepts both insurance and self-pay patients, making ADHD treatment accessible regardless of coverage status.

Typical Cash-Pay Costs:

• Initial evaluation: $150-$300
• Follow-up visits: $75-$150
• Monthly medication management: $50-$100

Medication Costs:

• Strattera (atomoxetine): $30-$400/month depending on dosage and whether generic is available
• Generic atomoxetine is often significantly cheaper than brand-name
• GoodRx and similar programs can reduce out-of-pocket costs

Provider Availability: A Key Advantage of Telehealth

One of telehealth’s greatest benefits is connecting patients with available providers, especially in areas with limited mental health resources. Rural communities often face provider shortages, with months-long waitlists for psychiatrists.

Telehealth platforms can dramatically reduce wait times by:

• Offering appointments within days or weeks rather than months
• Providing access to providers licensed in your state but practicing remotely
• Offering flexible scheduling including evenings and weekends
• Reducing geographic barriers to specialized ADHD care

Special Considerations and Patient Eligibility

When Telehealth ADHD Treatment May Not Be Appropriate

While telehealth expands access, it’s not right for everyone. You may need in-person evaluation if you have:

Complex Medical History:

• Uncontrolled cardiovascular disease requiring physical examination
• Severe mental health conditions needing in-person crisis management
• Active substance use disorders requiring comprehensive assessment
• Multiple comorbid conditions needing integrated care

Diagnostic Uncertainty:

• First-time ADHD diagnosis in young children (under 6-12 years)
• Complicated symptom presentation overlapping with other conditions
• Need for neuropsychological testing
• Requirement for school-based observations

Safety Concerns:

• Recent suicidal ideation or attempts
• Acute psychiatric symptoms requiring immediate intervention
• Unstable living situation without reliable telehealth access
• History of medication misuse requiring closer monitoring

Age-Specific Considerations

Adults (18+): Most telehealth platforms primarily serve adults, who are generally good candidates for virtual ADHD care. Adult ADHD diagnosis often involves retrospective childhood history, which can be effectively gathered via telehealth.

Adolescents (13-17): Some platforms treat teens with parental consent. Adolescents may need additional screening and monitoring, particularly given FDA warnings about suicidal thinking in young people starting Strattera.

Children (Under 13): Most telehealth services don’t treat young children for ADHD via telehealth alone. Pediatric ADHD diagnosis typically requires in-person evaluation, input from teachers, and sometimes psychoeducational testing.

Contraindications for Strattera

Your provider will screen for conditions that make Strattera unsafe:

• Narrow-angle glaucoma (absolute contraindication)
• Severe cardiovascular disease (requires careful risk-benefit analysis)
• Recent MAOI use (within 14 days—dangerous interaction)
• Liver disease (Strattera is metabolized by the liver)
• Severe allergic reactions to atomoxetine or ingredients

If any of these apply, your provider may recommend alternative non-stimulants or refer you for specialized in-person evaluation.

Safety, Quality, and Choosing a Reputable Provider

Warning Signs of Problematic Telehealth Services

The ADHD telehealth industry faced significant scrutiny in 2022-2023 when the DEA and DOJ investigated companies like Cerebral and Done for allegedly over-prescribing stimulants without adequate safeguards. These investigations led to important reforms across the industry.

Red flags to avoid:

• Guaranteed prescriptions before evaluation
• Minimal or no video consultation required
• No verification of medical history or identity
• Absence of follow-up care or monitoring
• Pressure to purchase medications from specific pharmacies
• Unwillingness to coordinate with your other healthcare providers
• No discussion of risks, alternatives, or non-medication treatments

What Quality Telehealth ADHD Care Looks Like

Reputable providers follow evidence-based practices:

Comprehensive Evaluation:

• Structured diagnostic interviews using DSM-5 criteria
• Assessment of symptom severity and functional impairment
• Review of childhood history and current symptoms
• Screening for comorbid conditions
• Consideration of differential diagnoses

Collaborative Treatment Planning:

• Discussion of all treatment options (medication and non-medication)
• Shared decision-making about which medication to try
• Clear explanation of expected benefits and potential risks
• Development of monitoring plan for safety and effectiveness

Ongoing Monitoring:

• Regular follow-up appointments (especially when starting medication)
• Tracking of symptom improvement using standardized measures
• Monitoring for side effects and safety concerns
• Willingness to adjust treatment based on response
• Coordination with your primary care provider when appropriate

Ethical Prescribing Practices:

• Checking prescription drug monitoring programs when applicable
• Requiring treatment agreements for controlled substances
• Periodic drug screening if clinically indicated
• Refusing inappropriate prescription requests
• Referring to in-person care when telehealth is insufficient

How Klarity Health Approaches ADHD Care

At Klarity Health, we’re committed to making quality ADHD treatment accessible while maintaining the highest clinical standards. Our approach includes:

Provider Availability: We connect you with licensed psychiatrists and nurse practitioners typically within 48 hours—far faster than traditional appointment wait times that can stretch months.

Transparent Pricing: We accept both insurance and cash-pay patients, with clear upfront pricing so you know exactly what to expect. No hidden fees or surprise bills.

Comprehensive Care: Our providers conduct thorough evaluations following evidence-based diagnostic criteria, discuss all treatment options including therapy referrals, and create individualized treatment plans.

Ongoing Support: We don’t just prescribe and disappear. Regular follow-ups ensure your treatment is working, side effects are managed, and your ADHD care evolves with your needs.

Practical Tips for Successful Telehealth ADHD Treatment

Before Your First Appointment

Gather Documentation:

• List of current and past medications
• Summary of previous ADHD treatments if any
• School records or report cards showing childhood attention issues
• Notes about specific symptoms and how they impact your life

Prepare Your Environment:

• Find a quiet, private space for your video appointment
• Test your internet connection and camera
• Have a pen and paper ready for notes
• Ensure adequate lighting so the provider can see you clearly

Think About Your Goals:

• What symptoms bother you most?
• How is ADHD affecting your work, relationships, or daily life?
• What have you tried before, and how did it work?
• What questions do you have about treatment options?

During Treatment

Be an Active Participant:

• Honestly report all symptoms, even uncomfortable ones
• Mention any side effects promptly
• Keep a symptom journal to track improvements
• Communicate openly about what’s working and what isn’t

Follow Your Treatment Plan:

• Take medication as prescribed (Strattera works best with consistent daily use)
• Attend all scheduled follow-ups
• Don’t adjust doses without consulting your provider
• Report any concerning changes in mood or physical symptoms

Consider Complementary Approaches:

• ADHD coaching or therapy can enhance medication effectiveness
• Organizational tools and systems
• Exercise and sleep hygiene
• Dietary considerations (though diet alone isn’t sufficient for most people)

Managing Your Medication

For Strattera Specifically:

• Can be taken with or without food (though taking with food may reduce nausea)
• May take 4-6 weeks for full effect—be patient
• Don’t stop abruptly if side effects occur; consult your provider first
• Store at room temperature away from moisture and heat
• Keep track of refills to avoid running out

Pharmacy Considerations:

• Choose a pharmacy you’ll use consistently
• Confirm they accept e-prescriptions from telehealth providers
• Ask about cost-saving programs if paying out of pocket
• Alert your provider if you have any issues filling prescriptions

What’s Next: The Future of Telehealth ADHD Treatment

Regulatory Outlook for 2026 and Beyond

The telehealth landscape continues to evolve. Here’s what experts anticipate:

Federal Level:The DEA’s temporary telehealth flexibilities for controlled substances are set to expire December 31, 2025. A fourth extension for 2026 is under review by the Office of Management and Budget. Industry observers expect either:

• Another temporary extension maintaining current flexibilities
• New permanent regulations establishing a framework for telehealth controlled substance prescribing (possibly including the proposed ‘Special Registration’ system)
• A hybrid approach requiring periodic in-person visits while allowing ongoing telehealth management

For non-stimulant medications: These regulatory changes won’t affect access to medications like Strattera, which will remain fully accessible via telehealth regardless of DEA rule changes.

State Level:States are moving in various directions:

• Some (like New Hampshire in 2025) are expanding permanent telehealth access
• Others (like New York) are implementing stricter requirements for controlled substances
• Most are strengthening prescription monitoring programs and safety protocols
• Several are considering expanding nurse practitioner scope of practice

Staying Informed and Prepared

If you’re currently in telehealth ADHD treatment:

• Stay in communication with your provider about any regulatory changes
• Attend all scheduled appointments to maintain continuity of care
• Ask about backup plans if regulations change
• Consider coordinating with a local provider for any required in-person visits

If you’re considering starting treatment:

• Don’t let regulatory uncertainty delay getting help you need
• Reputable providers will navigate any rule changes to maintain your care
• Focus on finding quality care now rather than waiting for perfect clarity

Most experts agree that telehealth ADHD treatment is here to stay in some form. The healthcare system has recognized its value in expanding access, and patients have demonstrated they can safely receive this care virtually when proper protocols are followed.

Taking the Next Step

If you’ve been struggling with ADHD symptoms and wondering whether telehealth treatment could help, the evidence is clear: for many people, virtual care offers an accessible, effective path to getting the support you need.

Non-stimulant medications like Strattera provide a particularly straightforward telehealth option, free from the regulatory complexities that sometimes complicate stimulant prescribing. With the right provider, you can receive comprehensive evaluation, evidence-based treatment, and ongoing support—all from the comfort of home.

Getting Started

Consider whether telehealth ADHD treatment is right for you:

• Do you have symptoms of inattention, hyperactivity, or impulsivity affecting your daily life?
• Have long wait times or limited local providers prevented you from seeking help?
• Would the convenience and flexibility of virtual appointments fit your schedule better?
• Are you interested in exploring non-stimulant medication options?

Choose a reputable provider:

• Look for platforms with licensed clinicians and comprehensive evaluations
• Verify they accept your insurance or offer transparent cash pricing
• Check that providers are licensed in your state
• Read reviews and ask about their approach to ADHD diagnosis and treatment

At Klarity Health, we make getting started simple:Our board-certified providers are available for appointments within 48 hours, offering both insurance-based and affordable cash-pay options. We’ll conduct a thorough ADHD evaluation, discuss all treatment options including non-stimulant medications, and create a personalized care plan that fits your life.

You Don’t Have to Navigate ADHD Alone

Living with untreated ADHD can feel overwhelming—affecting your work performance, relationships, self-esteem, and daily functioning. But effective treatment is more accessible than ever, and telehealth has removed many of the barriers that once stood between people and the care they need.

Whether you’re considering Strattera, want to explore other non-stimulant options, or simply need to talk with a qualified provider about your symptoms, telehealth offers a legitimate, safe, and convenient path forward.

Ready to take the next step? Klarity Health is here to help. Our experienced providers understand ADHD, and we’re committed to making quality care accessible to everyone who needs it—with fast appointment availability, transparent pricing, and comprehensive support every step of the way.

Don’t let ADHD symptoms continue to hold you back. The treatment you need may be just a video call away.

References

1. FierceHealthcare. (2024, November). ‘DEA finalizes one-year extension of controlled substance prescribing via telehealth.’ Retrieved from https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final

2. McDermott Will & Emery. (2025). ‘DEA signals extension of telemedicine flexibilities for controlled substance prescribing for 2026.’ Retrieved from https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/

3. Sheppard Mullin Healthcare Law Blog. (2025, August 15). ‘Telehealth and in-person visits: Tracking federal and state updates to pandemic-era telehealth exceptions.’ National Law Review. Retrieved from https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/

4. Medical News Today. (2025, January 14). ‘Is Strattera a controlled substance?’ Retrieved from https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance

5. RxAgent. (2025, October). ‘The telehealth compliance trap: What providers must know about state-by-state prescribing rules.’ Retrieved from https://www.rxagent.co/blog/telehealth-compliance-trap

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment